Combination of dextromethorphan and bupropion for treating depression in asian patients
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments with bupropion are ineffective for depression in Asian patients, and dextromethorphan plasma levels are not adequately maintained, leading to potential adverse events and reduced efficacy.
Innovation Solution
A combination of bupropion and dextromethorphan is administered once or twice daily to Asian patients, with specific metabolites or prodrugs of bupropion co-administered to increase dextromethorphan plasma levels and reduce adverse events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bupropion is administered alone to Asian patients, then the treatment simplicity is maintained, but the therapeutic efficacy is insufficient
Solution Approach 1:
The patent combines bupropion and dextromethorphan into a single medicament formulation, merging two therapeutic agents with complementary mechanisms of action. This combination approach addresses the insufficient efficacy of monotherapy while managing complexity through integrated formulation design
2Reliability
If dextromethorphan is administered at standard doses, then the dosage simplicity is maintained, but the plasma levels are not adequately maintained leading to adverse events
Solution Approach 1:
The patent modifies the dosing parameters of dextromethorphan when combined with bupropion, adjusting frequency and timing to maintain stable plasma levels. This parameter optimization ensures therapeutic efficacy while reducing adverse events associated with fluctuating drug levels
3Reliability
If bupropion is used as monotherapy, then the treatment cost is reduced, but the effectiveness for Asian patients is inadequate
Solution Approach 1:
The patent creates a composite medicament containing both bupropion and dextromethorphan, leveraging their synergistic effects. This composite formulation provides enhanced therapeutic effectiveness for Asian patients while consolidating multiple substances into a single coordinated treatment regimen
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.